Browse the evidence

Calorie restriction, structured exercise, pharmacotherapy, and metabolic surgeries have shown beneficial effects in reducing VAT.

Implementing these strategies can effectively reduce visceral fat.

Both liraglutide (3 mg) and naltrexone/bupropion (32/360 mg) improved body weight and composition, carbohydrate and lipid metabolism, and liver fat and function.

Practitioners can consider both liraglutide and naltrexone/bupropion as effective options for improving metabolic health in patients with obesity.

Lifestyle preventative approaches, especially combining nutrition and physical activity behavioral components, are essential in preventing multiple long-term conditions.

Practitioners should integrate nutrition and physical activity in prevention strategies.

Innovative exercise prescription should include different intensity-based approaches to target multiple long-term conditions.

Exercise programs should be tailored to individual needs and intensities.

Nutritional intake guidelines can be individualized to target multiple long-term conditions.

Nutrition plans should be customized to address specific health conditions.

CLA supplementation is associated with increased muscle variables or decreased adiposity variables.

CLA may be beneficial for individuals looking to improve muscle mass or reduce fat.

Bariatric surgery is associated with substantial weight reduction (20-30%) and markedly lower subsequent risk for major adverse cardiovascular events (MACE).

Bariatric surgery may be a highly effective option for patients with obesity at risk for cardiovascular events.

Newer antiobesity pharmacotherapies, particularly semaglutide and tirzepatide, have shown greater efficacy for weight reduction compared with older medications.

Newer medications may provide better options for weight management in patients with obesity.

Retatrutide resulted in a percentage change in weight from baseline to 24 weeks ranging from -7.2% to -~18% as the dose increased from 1 mg to 12 mg.

Retatrutide may be an effective treatment option for weight loss in individuals with obesity.

After 3 months, average weight loss was 4.11 kg or 4.57%.

Practitioners can expect significant weight loss in patients using semaglutide in a real-world setting.

Individuals lost fat mass (2.67 kg) and trunk fat mass (1.10 kg).

Practitioners can expect reductions in fat mass among patients using semaglutide.

Body composition improved with losses in fat mass and gains in overall proportion of lean muscle and skeletal muscle.

Practitioners can expect improvements in body composition with semaglutide treatment.

Exercise has emerged as a potent therapeutic in disease states characterized by the accelerated aging phenotype.

Implementing exercise programs can be crucial for managing diseases associated with aging.

Semaglutide 2.4 mg was associated with significantly greater weight loss compared to placebo in clinical trials lasting 68 weeks.

Semaglutide can be considered an effective pharmacotherapy for weight loss in adults with obesity or overweight.

Advances in metabolic surgery, pharmacologic therapy, and lifestyle modification have made remission of diabetes more feasible.

Healthcare providers should consider these advancements when discussing treatment options.

Both training groups (MC and UT) experienced significant increases in strength in the bench press (BP) and squat (SQ).

Both menstrual cycle-based and traditional training can effectively increase strength in trained women.

The menstrual cycle-based training group (MC) showed a significant improvement in countermovement jump (CMJ) performance.

Incorporating menstrual cycle considerations may enhance explosive strength training outcomes.

Meal replacement (MR) significantly reduced glycated hemoglobin A1c (HbA1c) by -0.46%, fasting blood glucose (FBG) by -0.62 mmol/L, body weight by -2.43 kg, and body mass index (BMI) by -0.65 compared to conventional diabetic diets (CDs).

Implementing meal replacement strategies can lead to significant improvements in glycemic control and weight management for T2D patients.

Total meal replacement showed greater improvement in HbA1c, FBG, body weight, and BMI compared to partial meal replacement.

Total meal replacement may be more effective than partial meal replacement for improving health markers in T2D patients.

Meal replacement with caloric restriction resulted in greater reductions in body weight and BMI compared to meal replacement without caloric restriction.

Incorporating caloric restriction into meal replacement strategies can enhance weight loss outcomes for T2D patients.

NN1706 treatment led to 8.2% weight loss from baseline after 10 weeks in adults with overweight/obesity.

NN1706 may be an effective treatment option for weight loss in adults with overweight or obesity.

Effective obesity management is essential to mitigate associated comorbidities and improve quality of life in menopausal women.

Healthcare providers should prioritize obesity management in menopausal women to enhance their health outcomes.

Tailored treatment strategies are necessary to address the unique challenges of obesity management during menopause.

Practitioners should develop individualized obesity management plans for menopausal women.

The ELM trial tests the hypothesis that a habit-based lifestyle treatment can produce sustained remission of metabolic syndrome (MetS) at 24 months.

Practitioners may consider implementing habit-based lifestyle interventions for MetS management.